Sep. 10 at 8:45 PM
Freedom Capital Markets analyst Keith Hinton initiated coverage of Pulse Biosciences with a Buy rating and a
$73 price target, sparking renewed investor interest in the bioelectric medicine company. The target implies substantial upside from current levels and comes as the stock approaches its 52-week high of
$58.90, after rising sharply from its 52-week low of
$12.56.
Hinton’s bullish thesis centers on the atrial fibrillation ablation market, which he views as large, growing and ripe for disruption by Pulse Biosciences’ proprietary nanosecond pulsed field ablation (nsPFA) technology. Freedom also highlighted the company’s strong balance sheet and strategic positioning, which it believes provide sufficient financial support to reach the next major clinical data catalyst.
A key part of the thesis is the NANOPULSE-AF trial, with results expected around the second quarter of 2027.
$PLSE